Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Liabilities (2021 - 2025)

Rxo's Total Liabilities history spans 5 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Total Liabilities fell 3.66% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, down 3.66%, while the annual FY2025 figure was $1.7 billion, 3.66% down from the prior year.
  • Total Liabilities reached $1.7 billion in Q4 2025 per RXO's latest filing, up from $1.6 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q4 2024 to a low of -$1.2 billion in Q2 2022.
  • Average Total Liabilities over 5 years is $1.0 billion, with a median of $1.3 billion recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 237.39% in 2023, then dropped 15.07% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $998.0 million in 2021, then skyrocketed by 44.69% to $1.4 billion in 2022, then decreased by 14.75% to $1.2 billion in 2023, then surged by 46.39% to $1.8 billion in 2024, then decreased by 3.66% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RXO's Total Liabilities are $1.7 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.6 billion (Q2 2025).